Lupin receives tentative approval for Efinaconazole Topical Solution

26 Dec 2020 Evaluate

Lupin has received tentative approval for its Efinaconazole Topical Solution, 10%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Jublia Topical Solution, 10%, of Bausch Health Americas, Inc.

Efinaconazole Topical Solution, 10%, is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole Topical Solution, 10%, (RLD: Jublia) had estimated annual sales of $222.9 million in the U.S. (IQVIA MAT September 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

1629.45 -30.50 (-1.84%)
21-May-2024 09:22 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1524.10
Dr. Reddys Lab 5794.00
Cipla 1405.15
Zydus Lifesciences 1130.50
Lupin 1629.45
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.